CORDIS
EU research results

CORDIS

English EN
MICROBiome-based biomarkers to PREDICT decompensation of liver cirrhosis and treatment response

MICROBiome-based biomarkers to PREDICT decompensation of liver cirrhosis and treatment response

Objective

Decompensation of liver cirrhosis and progression towards acute-on-chronic liver failure (ACLF) causes 1.2 million deaths/year. Microbiome is causally involved in cirrhosis progression and is for drugs the first interaction point with the patients. Drugs can alter the microbiome leading to unwanted effects or even facilitating their effects, but the microbiome metabolizes the drugs, shapes their effects and possibly determines the host response to drugs. As each person carries an individual microbiome, insight in these processes should help stratify or even personalize patient health care and treatment.
The aims of MICROB-PREDICT are 1) to better understand the role of microbiome and the gut-liver-axis interactome with respect to microbiome functionalities, 2) to identify and validate microbiome-based biomarkers and signatures for personalized prediction of decompensation and ACLF, and response to treatment, 3) to design three new tests as easy-to-use tools and point-of-care, smartphone-connected nanobiosensors, and 4) to validate them in a randomized controlled trial. MICROB-PREDICT will assemble existing data and samples from major microbiome initiatives in hepatology (12 international studies, >10,000 patients), and enrich them with holistic and in-depth analysis using cutting-edge multi-omics technologies of host and microbiome from different body sites in samples of >1,000 patients collected in a longitudinal manner with sequential visits and controlling for confounders.
MICROB-PREDICT results will foster more accurate, personalized risk stratification and significant steps towards personalized treatment of decompensated cirrhosis and ACLF. World-leading microbiome specialists, technology leaders and clinical experts make this a programme of scientific excellence; patient organisations (ELPA) and the European Association for the study of the Liver (EASL) will channel our results into a powerful dissemination, communication and exploitation programme.
Leaflet | Map data © OpenStreetMap contributors, Credit: EC-GISCO, © EuroGeographics for the administrative boundaries

Coordinator

EUROPEAN FOUNDATION FOR THE STUDY OF CHRONIC LIVER FAILURE (EF-CLIF)

Address

Travessera De Gracia 11, 7th Floor
08021 Barcelona

Spain

Activity type

Higher or Secondary Education Establishments

EU Contribution

€ 2 273 400

Participants (21)

Sort alphabetically

Sort by EU Contribution

Expand all

DEBRECENI EGYETEM

Hungary

EU Contribution

€ 347 000

ODENSE UNIVERSITETSHOSPITAL

Denmark

EU Contribution

€ 800 000

KOBENHAVNS UNIVERSITET

Denmark

EU Contribution

€ 1 246 100

EUROPEAN MOLECULAR BIOLOGY LABORATORY

Germany

EU Contribution

€ 2 021 900

COMMISSARIAT A L ENERGIE ATOMIQUE ET AUX ENERGIES ALTERNATIVES

France

EU Contribution

€ 648 000

MAX-PLANCK-GESELLSCHAFT ZUR FORDERUNG DER WISSENSCHAFTEN EV

Germany

EU Contribution

€ 996 000

VAIOMER

France

EU Contribution

€ 484 000

INSTITUT NATIONAL DE LA RECHERCHE AGRONOMIQUE

France

EU Contribution

€ 620 000

JOHANN WOLFGANG GOETHE-UNIVERSITATFRANKFURT AM MAIN

Germany

EU Contribution

€ 635 000

KATHOLIEKE UNIVERSITEIT LEUVEN

Belgium

EU Contribution

€ 620 000

ACADEMISCH ZIEKENHUIS LEIDEN

Netherlands

EU Contribution

€ 500 500

UNIVERSITAT DE BARCELONA

Spain

EU Contribution

€ 224 000

BIOBYTE SOLUTIONS GMBH

Germany

EU Contribution

€ 290 000

FUNDACIO INSTITUT CATALA DE NANOCIENCIA I NANOTECNOLOGIA

Spain

EU Contribution

€ 1 089 400

UNIVERSITY COLLEGE LONDON

United Kingdom

EU Contribution

€ 423 500

UNIVERSITETET I OSLO

Norway

EU Contribution

€ 150 000

EUROPEAN LIVER PATIENTS ASSOCIATION

Belgium

EU Contribution

€ 80 000

Concentris Research Management GmbH

Germany

EU Contribution

€ 535 000

KING'S COLLEGE LONDON

United Kingdom

EU Contribution

€ 500 000

FUNDACIO CLINIC PER A LA RECERCA BIOMEDICA

Spain

EU Contribution

€ 460 000

EUROPEAN ASSOCIATION FOR THE STUDYOF THE LIVER

Switzerland

EU Contribution

€ 56 200

Project information

Grant agreement ID: 825694

Status

Ongoing project

  • Start date

    1 January 2019

  • End date

    31 March 2025

Funded under:

H2020-EU.3.1.2.

  • Overall budget:

    € 15 000 002,50

  • EU contribution

    € 15 000 000

Coordinated by:

EUROPEAN FOUNDATION FOR THE STUDY OF CHRONIC LIVER FAILURE (EF-CLIF)

Spain